Navigation Links
Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase,I/IIa 6-Month Results at 75th Annual Meeting of the American,Association of Neurological Surgeons

mance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    BLSI Contact:

    Sharon Correia

    508 497 2360 x224
scorreia@bostonlifesciences.com

Boston Life Sciences, Inc.

CONTACT: Sharon Correia, Director of Corporate Communications and InvestorRelations of Boston Life Sciences, Inc., +1-508-497-2360, ext. 224, scorreia@bostonlifesciences.com

Web site: http://www.bostonlifesciences.com/

Ticker Symbol: (NASDAQ-NMS:BLSI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 1Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 2Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 4Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 5StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 1StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 2StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 3StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 4National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 1National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 2National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 3National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 4